RU2010120845A - Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний - Google Patents
Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний Download PDFInfo
- Publication number
- RU2010120845A RU2010120845A RU2010120845/04A RU2010120845A RU2010120845A RU 2010120845 A RU2010120845 A RU 2010120845A RU 2010120845/04 A RU2010120845/04 A RU 2010120845/04A RU 2010120845 A RU2010120845 A RU 2010120845A RU 2010120845 A RU2010120845 A RU 2010120845A
- Authority
- RU
- Russia
- Prior art keywords
- pyrrolidin
- methoxy
- phenyl
- diseases
- melatonergic
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 11
- 201000010099 disease Diseases 0.000 title claims abstract 8
- 230000002265 prevention Effects 0.000 title claims abstract 4
- VDQQJMHXZCMNMU-UHFFFAOYSA-N 1-phenylpyrrolidine Chemical class C1CCCN1C1=CC=CC=C1 VDQQJMHXZCMNMU-UHFFFAOYSA-N 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract 6
- 206010022437 insomnia Diseases 0.000 claims abstract 6
- 230000007170 pathology Effects 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 3
- 208000000044 Amnesia Diseases 0.000 claims abstract 3
- 208000019901 Anxiety disease Diseases 0.000 claims abstract 3
- 208000026139 Memory disease Diseases 0.000 claims abstract 3
- 208000019695 Migraine disease Diseases 0.000 claims abstract 3
- 208000008589 Obesity Diseases 0.000 claims abstract 3
- 206010033664 Panic attack Diseases 0.000 claims abstract 3
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 3
- 208000028017 Psychotic disease Diseases 0.000 claims abstract 3
- 208000006011 Stroke Diseases 0.000 claims abstract 3
- 230000032683 aging Effects 0.000 claims abstract 3
- 230000036506 anxiety Effects 0.000 claims abstract 3
- 230000036528 appetite Effects 0.000 claims abstract 3
- 235000019789 appetite Nutrition 0.000 claims abstract 3
- 230000027288 circadian rhythm Effects 0.000 claims abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 3
- 210000002249 digestive system Anatomy 0.000 claims abstract 3
- 208000035475 disorder Diseases 0.000 claims abstract 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract 3
- 206010015037 epilepsy Diseases 0.000 claims abstract 3
- 230000001771 impaired effect Effects 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 229940126601 medicinal product Drugs 0.000 claims abstract 3
- 230000006984 memory degeneration Effects 0.000 claims abstract 3
- 208000023060 memory loss Diseases 0.000 claims abstract 3
- 206010027599 migraine Diseases 0.000 claims abstract 3
- 235000020824 obesity Nutrition 0.000 claims abstract 3
- 208000019906 panic disease Diseases 0.000 claims abstract 3
- 230000001575 pathological effect Effects 0.000 claims abstract 3
- 201000000980 schizophrenia Diseases 0.000 claims abstract 3
- 208000012672 seasonal affective disease Diseases 0.000 claims abstract 3
- 208000019116 sleep disease Diseases 0.000 claims abstract 3
- 230000035882 stress Effects 0.000 claims abstract 3
- LRSLJDKEWRAQMZ-LLVKDONJSA-N 1-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]cyclopropane-1-carboxamide Chemical compound COC1=CC=CC(N2C[C@@H](CC2)C2(CC2)C(N)=O)=C1 LRSLJDKEWRAQMZ-LLVKDONJSA-N 0.000 claims abstract 2
- ZYCJOIXTTRTPPP-VIFPVBQESA-N 2,2,2-trifluoro-n-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]acetamide Chemical compound COC1=CC=CC(N2C[C@H](CC2)NC(=O)C(F)(F)F)=C1 ZYCJOIXTTRTPPP-VIFPVBQESA-N 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- UJYFWBHTOBRJNK-LBPRGKRZSA-N n-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]-2,2-dimethylpropanamide Chemical compound COC1=CC=CC(N2C[C@H](CC2)NC(=O)C(C)(C)C)=C1 UJYFWBHTOBRJNK-LBPRGKRZSA-N 0.000 claims abstract 2
- KUOOFEYJCRNFOO-LBPRGKRZSA-N n-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]-2-methylpropanamide Chemical compound COC1=CC=CC(N2C[C@H](CC2)NC(=O)C(C)C)=C1 KUOOFEYJCRNFOO-LBPRGKRZSA-N 0.000 claims abstract 2
- KNVMZTZPDNRYEJ-ZDUSSCGKSA-N n-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]-3-methylbutanamide Chemical compound COC1=CC=CC(N2C[C@H](CC2)NC(=O)CC(C)C)=C1 KNVMZTZPDNRYEJ-ZDUSSCGKSA-N 0.000 claims abstract 2
- FQBMUJPNQAMQSX-NSHDSACASA-N n-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]acetamide Chemical compound COC1=CC=CC(N2C[C@H](CC2)NC(C)=O)=C1 FQBMUJPNQAMQSX-NSHDSACASA-N 0.000 claims abstract 2
- BDYQJTXTXBSBMC-LBPRGKRZSA-N n-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]butanamide Chemical compound C1[C@@H](NC(=O)CCC)CCN1C1=CC=CC(OC)=C1 BDYQJTXTXBSBMC-LBPRGKRZSA-N 0.000 claims abstract 2
- HUNZQHPOZLXJNI-NSHDSACASA-N n-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]propanamide Chemical compound C1[C@@H](NC(=O)CC)CCN1C1=CC=CC(OC)=C1 HUNZQHPOZLXJNI-NSHDSACASA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- RDVWEXSYTNNSLM-NSHDSACASA-N 1-ethyl-3-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]urea Chemical compound C1[C@@H](NC(=O)NCC)CCN1C1=CC=CC(OC)=C1 RDVWEXSYTNNSLM-NSHDSACASA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 abstract 1
- -1 ethyl (S) - [1- (3-methoxy-phenyl) -pyrrolidin-3-yl] carbamate Chemical class 0.000 abstract 1
- CFJDFLKIXFRYLR-JTQLQIEISA-N methyl n-[(3s)-1-(3-methoxyphenyl)pyrrolidin-3-yl]carbamate Chemical compound C1[C@@H](NC(=O)OC)CCN1C1=CC=CC(OC)=C1 CFJDFLKIXFRYLR-JTQLQIEISA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702800A ES2331276B1 (es) | 2007-10-25 | 2007-10-25 | Compuestos de fenilpirrolidina. |
| ESP200702800 | 2007-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010120845A true RU2010120845A (ru) | 2011-11-27 |
Family
ID=40291255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010120845/04A RU2010120845A (ru) | 2007-10-25 | 2008-10-23 | Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120184594A1 (enExample) |
| EP (1) | EP2203422B1 (enExample) |
| JP (1) | JP2011500764A (enExample) |
| KR (1) | KR20100072287A (enExample) |
| CN (1) | CN101878198A (enExample) |
| AR (1) | AR069002A1 (enExample) |
| AT (1) | ATE513809T1 (enExample) |
| AU (1) | AU2008316473A1 (enExample) |
| BR (1) | BRPI0817660A2 (enExample) |
| CA (1) | CA2703458A1 (enExample) |
| CL (1) | CL2008003141A1 (enExample) |
| DK (1) | DK2203422T3 (enExample) |
| ES (2) | ES2331276B1 (enExample) |
| MX (1) | MX2010004469A (enExample) |
| PL (1) | PL2203422T3 (enExample) |
| PT (1) | PT2203422E (enExample) |
| RU (1) | RU2010120845A (enExample) |
| SI (1) | SI2203422T1 (enExample) |
| TW (1) | TW200920353A (enExample) |
| UY (1) | UY31425A1 (enExample) |
| WO (1) | WO2009053441A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753709A (en) * | 1995-06-07 | 1998-05-19 | Bristol-Myers Squibb Company | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics |
| DE60007745T2 (de) * | 1999-06-30 | 2005-03-10 | Bristol-Myers Squibb Co. | Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe |
-
2007
- 2007-10-25 ES ES200702800A patent/ES2331276B1/es not_active Withdrawn - After Issue
-
2008
- 2008-10-23 DK DK08842890.9T patent/DK2203422T3/da active
- 2008-10-23 AT AT08842890T patent/ATE513809T1/de active
- 2008-10-23 AR ARP080104616A patent/AR069002A1/es not_active Application Discontinuation
- 2008-10-23 BR BRPI0817660A patent/BRPI0817660A2/pt not_active IP Right Cessation
- 2008-10-23 SI SI200830368T patent/SI2203422T1/sl unknown
- 2008-10-23 EP EP08842890A patent/EP2203422B1/en not_active Not-in-force
- 2008-10-23 JP JP2010530463A patent/JP2011500764A/ja not_active Abandoned
- 2008-10-23 CN CN2008801131031A patent/CN101878198A/zh active Pending
- 2008-10-23 PL PL08842890T patent/PL2203422T3/pl unknown
- 2008-10-23 WO PCT/EP2008/064390 patent/WO2009053441A1/en not_active Ceased
- 2008-10-23 AU AU2008316473A patent/AU2008316473A1/en not_active Abandoned
- 2008-10-23 MX MX2010004469A patent/MX2010004469A/es active IP Right Grant
- 2008-10-23 US US12/739,708 patent/US20120184594A1/en not_active Abandoned
- 2008-10-23 PT PT08842890T patent/PT2203422E/pt unknown
- 2008-10-23 CA CA2703458A patent/CA2703458A1/en not_active Abandoned
- 2008-10-23 KR KR1020107008900A patent/KR20100072287A/ko not_active Withdrawn
- 2008-10-23 RU RU2010120845/04A patent/RU2010120845A/ru not_active Application Discontinuation
- 2008-10-23 ES ES08842890T patent/ES2368697T3/es active Active
- 2008-10-24 UY UY31425A patent/UY31425A1/es unknown
- 2008-10-24 TW TW097140810A patent/TW200920353A/zh unknown
- 2008-10-24 CL CL2008003141A patent/CL2008003141A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE513809T1 (de) | 2011-07-15 |
| EP2203422A1 (en) | 2010-07-07 |
| WO2009053441A1 (en) | 2009-04-30 |
| BRPI0817660A2 (pt) | 2015-09-29 |
| ES2331276A1 (es) | 2009-12-28 |
| PT2203422E (pt) | 2011-09-26 |
| CA2703458A1 (en) | 2009-04-30 |
| ES2368697T3 (es) | 2011-11-21 |
| ES2331276B1 (es) | 2010-10-21 |
| TW200920353A (en) | 2009-05-16 |
| UY31425A1 (es) | 2009-04-30 |
| SI2203422T1 (sl) | 2011-10-28 |
| CN101878198A (zh) | 2010-11-03 |
| PL2203422T3 (pl) | 2011-11-30 |
| AU2008316473A1 (en) | 2009-04-30 |
| US20120184594A1 (en) | 2012-07-19 |
| CL2008003141A1 (es) | 2009-03-06 |
| KR20100072287A (ko) | 2010-06-30 |
| JP2011500764A (ja) | 2011-01-06 |
| MX2010004469A (es) | 2010-07-06 |
| EP2203422B1 (en) | 2011-06-22 |
| AR069002A1 (es) | 2009-12-23 |
| DK2203422T3 (da) | 2011-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101140510B1 (ko) | 우울증 치료용 로티고틴의 용도 | |
| JP2010504950A5 (enExample) | ||
| CL2012001501A1 (es) | Co-cristal constituido por agomelatina y un acido organico que presenta un estado solido a temperatura ambiente; procedimientos de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos del sistema melatoninergico tales como estres, trastornos del sueño y trastornos de ansiedad generalizada, entre otros. | |
| AU2011324414B2 (en) | Trans-2-decenoic acid derivative and pharmaceutical agent containing the same | |
| JP2015521642A5 (enExample) | ||
| RU2015146305A (ru) | Галактоолигосахаридная композиция и ее применение для предотвращения или лечения когнитивной дисфункции и эмоциональных расстройств при психоневрологических заболеваниях или старении | |
| CN1927193B (zh) | 阿戈美拉汀在获得用于治疗抑郁患者睡眠障碍的药物中的用途 | |
| JP2015521643A5 (enExample) | ||
| RU2010120847A (ru) | Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| JP2011518859A5 (enExample) | ||
| RU2012101227A (ru) | 1-(2-алкил-2,3-дигидро-бензофуран-4-ил)-пирролидин-3-иламинацильные соединения, фармацевтическая композиция и лекарственное средство на их основе и способ лечения или предупреждения мелатонергетических нарушений с их помощью | |
| RU2010120845A (ru) | Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| JP5634529B2 (ja) | 強迫性障害（ｏｃｄ）処置用の薬剤の製造のためのアゴメラチンの使用 | |
| WO2009127737A1 (en) | Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients | |
| AU2005314935A1 (en) | Preventive or therapeutic agent for sleep disorder | |
| KR20110011748A (ko) | 각성을 향상시키는 방법 | |
| RU2010120846A (ru) | Соединения 2,3-дигидробензофурана, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| RU2007102290A (ru) | Способ лечения нарушений и заболеваний нервной системы | |
| HRP20090632T1 (hr) | Novi derivati naftalena, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
| EP2127673A4 (en) | PHARMACEUTICAL AGENT FOR THE PREVENTION AND TREATMENT OF SKIN DISORDERS BY ACCELERATED KERATINISATION | |
| AR070003A1 (es) | Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| WO2006105455A3 (en) | Methods of treatment utilizing certain melatonin derivatives | |
| Srinivasan et al. | Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment | |
| AR070004A1 (es) | Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| JP2012509860A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20121016 |